Lead-212

Overview

Short-lived alpha-emitting isotope used in targeted alpha therapy; sourced primarily from a single aging DOE reactor at Oak Ridge, creating supply concentration risk that Bicycle Therapeutics addressed by leasing reprocessed uranium. Lead-212 is a targeted alpha therapy isotope whose short half-life allows exquisite tumor targeting via peptides: the radioisotope concentrates in cancer cells and clears systemic circulation rapidly, yielding effective and safer treatment than prior modalities. As of 2026, lead-212 has essentially a single primary production source — the US Department of Energy High Flux Reactor at Oak Ridge, Tennessee, described as aging and intermittently going offline — creating critical supply chain concentration risk for any program depending on it. (Segment 5 (20:00-25:00))